This content is from: Premium Short Sellers Won in Mallinckrodt Mess, but Some Hedgies Held On The specialty pharmaceutical company settled opioid lawsuit and is considering restructuring. By Michelle Celarier September 10, 2019
This content is from: Premium Bill Ackman Finishes 2019 With a Bang Pershing Square triumphs, making back four years of losses — and earning incentive fees. By Michelle Celarier January 03, 2020
This content is from: Portfolio Morning Brief: Suddenly Valeant’s Stock is Surging Shares of Valeant Pharmaceuticals International jumped more than 23 percent in just three days. By Stephen Taub November 09, 2017
This content is from: Premium Bill Ackman Has Some Advice for You — and It’s Not About Your Portfolio The Pershing Square CEO opined on life, love, and the pursuit of profit at an investment conference in Manhattan. By Michelle Celarier April 17, 2019
This content is from: Premium For ValueAct, There is Life After Valeant The activist hedge fund’s 2017 performance was buoyed by a large position in Twenty-First Century Fox. By Stephen Taub January 31, 2018
This content is from: Premium Short Seller Fahmi Quadir’s Hedge Fund in ‘Near Constant Battle’ Famous for her Valeant short call, she launched Safkhet Capital in 2018 — and quickly encountered the challenges of running a short-selling fund. By Michelle Celarier October 24, 2018
Sponsored New Research: The Implications of Today’s Rapidly Evolving Business Models Sponsored by PGIM February 20, 2020
Sponsored How Global Business Leaders View Today’s Transformative New Corporate Models Sponsored by PGIM February 20, 2020
